Comparing high and low amyloid producers in Alzheimer's disease: An in-depth analysis
Overall, our study supports the surrogate use of the Aβ<sub>42/40</sub> ratio as an equivalent to Aβ<sub>42</sub> to define AD. We showed that HiA CSF profiles were not associated with differences in cognition, brain structures and metabolism, APOE genotype tau CSF biomarkers or the rates of cognitive decline, but may be the associated with later-onset and early-stage AD.
Authors
- Emilie Skrobala
- Vincent Huin (ORCID: https://orcid.org/0000-0001-8201-5406)
- Anne Laure Aziz
- Simon Lecerf
- Florence Pasquier (ORCID: https://orcid.org/0000-0001-9880-9788)
- Susanna Schraen
- Maxime Bertoux (ORCID: https://orcid.org/0000-0002-5283-503X)
- Mélanie Leroy (ORCID: https://orcid.org/0000-0002-6630-394X)
- Vincent Deramecourt (ORCID: https://orcid.org/0000-0001-9742-7833)
- Thibaud Lebouvier (ORCID: https://orcid.org/0000-0002-4386-6045)
Institutions
- Inserm (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Lille Neurosciences & Cognition (FR)
Publication Details
- Journal
- Revue Neurologique
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1016/j.neurol.2025.02.004
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16